|
Jun 14
|
Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
|
|
Jun 11
|
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
|
|
May 14
|
Update: Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
|
|
May 14
|
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
|
|
May 14
|
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
|
|
May 13
|
Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy
|
|
May 13
|
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
|
|
May 13
|
Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate
|
|
May 13
|
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
|
|
May 10
|
Catalyst's New CEO Has Big Ideas For The Small Biotech
|
|
May 9
|
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
|
|
May 9
|
Takeda tackles $900m restructuring plan after generics hurt annual profits
|
|
May 9
|
Takeda targets ‘efficiency’ in restructuring, pipeline cuts
|
|
May 9
|
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss
|
|
May 9
|
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
|
|
May 8
|
Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations
|
|
Apr 29
|
Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
|
|
Apr 26
|
Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
|
|
Apr 26
|
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
|
|
Apr 26
|
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
|